Location History:
- Pasadena, CA (US) (2019)
- Arcadia, CA (US) (2020)
Company Filing History:
Years Active: 2019-2020
Title: Harry Ming Tak Choi: Innovator in Hybridization Chain Reaction Technologies
Introduction
Harry Ming Tak Choi is a notable inventor based in Arcadia, CA (US). He has made significant contributions to the field of immunohistochemistry through his innovative approaches to hybridization chain reaction (HCR) technologies. With a total of 2 patents, Choi's work has advanced the understanding and application of HCR in various scientific contexts.
Latest Patents
Choi's latest patents include groundbreaking methods that enhance the effectiveness of HCR reactions. The first patent, titled "Immunohistochemistry via Hybridization Chain Reaction," focuses on methods that utilize trigger oligos to activate probes, initiating the HCR process. The second patent, "Fractional Initiator Hybridization Chain Reaction," describes methods and compositions that involve split initiators. These split initiators must be brought into proximity, often through binding events mediated by a target, to form a complete initiator capable of triggering HCR signal amplification.
Career Highlights
Throughout his career, Choi has worked with prestigious organizations, including the California Institute of Technology and Molecular Instruments, Inc. His work in these institutions has allowed him to explore and develop innovative solutions in the realm of molecular biology and biochemistry.
Collaborations
Choi has collaborated with esteemed colleagues such as Niles A. Pierce and Naeem S. Husain. These partnerships have fostered a collaborative environment that has led to significant advancements in HCR technologies.
Conclusion
Harry Ming Tak Choi's contributions to hybridization chain reaction technologies have positioned him as a key figure in the field of immunohistochemistry. His innovative patents and collaborations reflect his commitment to advancing scientific knowledge and applications.